Extended Data Fig. 2: Characterization of anti-RBDDelta IgG1, IgG2b and IgG2c following the vaccination of RBDDelta, mRNA or RBDDelta/C3d mRNA mixture, or RBDDelta-C3d fusion mRNA. | Nature Biomedical Engineering

Extended Data Fig. 2: Characterization of anti-RBDDelta IgG1, IgG2b and IgG2c following the vaccination of RBDDelta, mRNA or RBDDelta/C3d mRNA mixture, or RBDDelta-C3d fusion mRNA.

From: Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA

Extended Data Fig. 2

a, MFIs of IgG subclasses obtained from Luminex assay measuring serological antibody binding against the RBD antigen from the Delta variant of SARS-CoV-2. Data related to Fig. 3i. b, Ratio of IgG2c to IgG1 levels as a surrogate of Th1-Th2 bias. Ratios were calculated as log10(MFIIgG2c)/log10(MFIIgG1). n = 5, statistical significance was analysed using a one-way ANOVA with post-hoc Tukey test. Data are presented as mean ± SD.

Back to article page